ERBB2 and cancer: But patients with higher HER2 expression levels did have worse disease-free survival in TCGA, indicating that HER2 may not act as a main cancer driver-gene in PDAC but still actively participating in the carcinogenesis of PDAC, thus made it an actionable target for clinical treatment.